Skip to content
Subscriber Only

Short Seller Andrew Left Says Valeant’s a Buy as Funds Exit

  • Left says Valeant is ‘priced right now like it’s over’
  • Funds like Jana, T. Rowe Price, Brahman sold last quarter
Video player cover image

Andrew Left: Valeant May See Higher Before It Sees Lower

Updated on

Andrew Left, the short seller whose report on Valeant Pharmaceuticals International Inc. triggered the drugmaker’s tailspin, is a buyer of the stock now that many funds are exiting.

“I’m long for a trade,” Left said by telephone, confirming comments he made earlier to the TheStreet.com. “Valeant is priced right now like it’s over.”